Biogen Inc.

Biogen Inc. is a multinational biotechnology company headquartered in Cambridge, Massachusetts, United States. Founded in 1978, the company's core mission is to pioneer innovative science to discover, develop, and deliver new medicines that transform the lives of patients and create value for shareholders and communities.

Biogen focuses on developing therapies for complex and devastating neurological diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Its product portfolio includes treatments such as Tecfidera, Vumerity, Tysabri, and Spinraza, alongside co-developed treatments for Alzheimer's disease like Leqembi. The company also has a presence in immunology and rare diseases, offering biosimilars and advancing a pipeline in these areas.

Led by President and CEO Christopher A. Viehbacher, who was appointed in November 2022, Biogen continues to navigate a dynamic market. Recent notable activities in early 2026 include reporting Q1 2026 results with a 2% year-over-year revenue increase, a proposed acquisition of Apellis Pharmaceuticals to enhance its immunology and rare disease portfolio, and FDA approval for a new high-dose regimen of SPINRAZA®. The company also entered an agreement with TJ Biopharma for felzartamab assets in Greater China and presented positive Phase 2 trial data for litifilimab in cutaneous lupus erythematosus.